These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23339448)

  • 1. Role of serum high mobility group box 1 in hematological malignancies complicated with systemic inflammatory response syndrome and effect of recombinant thrombomodulin.
    Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Sakai H; Kato M; Takahashi M; Miura I
    Leuk Lymphoma; 2013 Sep; 54(9):1953-8. PubMed ID: 23339448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-mobility group box 1 protein and hematologic malignancies with severe inflammation: therapeutic intervention with recombinant thrombomodulin.
    Melachrinou M
    Leuk Lymphoma; 2013 Sep; 54(9):1862-3. PubMed ID: 23369040
    [No Abstract]   [Full Text] [Related]  

  • 3. Recombinant Thrombomodulin Modulates Murine Colitis Possibly via High-Mobility Group Box 1 Protein Inhibition.
    Ueda T; Higashiyama M; Narimatsu K; Yasutake Y; Kurihara C; Okada Y; Watanabe C; Yoshikawa K; Maruta K; Komoto S; Tomita K; Nagao S; Hokari R; Miura S
    Digestion; 2015; 92(2):108-19. PubMed ID: 26302768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Recombinant Human Soluble Thrombomodulin in Treating Disseminated Intravascular Coagulation Complicating Allogeneic Hematopoietic Stem Cell Transplantation.
    Inoue Y; Matsunawa M; Sano F; Miura I
    Acta Haematol; 2018; 140(2):121-127. PubMed ID: 30227394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of serum high-mobility group box protein 1 level with outcomes of acute exacerbation of idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia.
    Shimizu H; Sakamoto S; Isshiki T; Furuya K; Kurosaki A; Homma S
    PLoS One; 2018; 13(5):e0196558. PubMed ID: 29795561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy of early use of recombinant soluble thrombomodulin for disseminated intravascular coagulation complicated with hematologic malignancies].
    Usami M; Kuroda H; Yoshida M; Sakamoto H; Shimoyama S; Kanari Y; Yamada M; Abe T; Fujii S; Maeda M
    Rinsho Ketsueki; 2015 Jun; 56(6):673-80. PubMed ID: 26256878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy.
    Nomura S; Fujita S; Ozasa R; Nakanishi T; Miyaji M; Mori S; Ito T; Ishii K
    Platelets; 2011; 22(5):396-7. PubMed ID: 21438846
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of serum high-mobility group box 1 protein elevation on oxygenation impairment after thoracic aortic aneurysm repair.
    Kohno T; Anzai T; Shimizu H; Kaneko H; Sugano Y; Yamada S; Yoshikawa T; Ishizaka A; Yozu R; Ogawa S
    Heart Vessels; 2011 May; 26(3):306-12. PubMed ID: 21052685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-mobility group box 1 as a surrogate prognostic marker in dogs with systemic inflammatory response syndrome.
    Yu DH; Nho DH; Song RH; Kim SH; Lee MJ; Nemzek JA; Park J
    J Vet Emerg Crit Care (San Antonio); 2010 Jun; 20(3):298-302. PubMed ID: 20636982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies.
    Kawano N; Fukatsu M; Yamakawa K; Seki Y; Wada H; Okamoto K; Ikezoe T
    Int J Hematol; 2024 Apr; 119(4):416-425. PubMed ID: 38270783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma high-mobility group box 1 (HMGB1) in dogs with various diseases: comparison with C-reactive protein.
    Ishida A; Ohno K; Fukushima K; Nakashima K; Takahashi M; Goto-Koshino Y; Fujino Y; Tsujimoto H
    J Vet Med Sci; 2011 Sep; 73(9):1127-32. PubMed ID: 21558736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial.
    Yamato M; Minematsu Y; Fujii J; Mori K; Minato T; Miyagawa S; Fujimura R; Morikage N; Arata Y; Nakano C; Wada A; Ito T
    Ther Apher Dial; 2013 Oct; 17(5):472-6. PubMed ID: 24107274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human soluble thrombomodulin prevents peripheral HMGB1-dependent hyperalgesia in rats.
    Tanaka J; Seki Y; Ishikura H; Tsubota M; Sekiguchi F; Yamaguchi K; Murai A; Umemura T; Kawabata A
    Br J Pharmacol; 2013 Nov; 170(6):1233-41. PubMed ID: 24004409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Roles of thrombomodulin as a nuclear safeguard].
    Ito T
    Nihon Yakurigaku Zasshi; 2014 Jan; 143(1):18-21. PubMed ID: 24420132
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant human soluble thrombomodulin ameliorates cerebral ischemic injury through a high-mobility group box 1 inhibitory mechanism without hemorrhagic complications in mice.
    Nakamura Y; Nakano T; Irie K; Sano K; Tanaka J; Yamashita Y; Satho T; Matsuo K; Fujioka M; Ishikura H; Mishima K
    J Neurol Sci; 2016 Mar; 362():278-82. PubMed ID: 26944163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome.
    Kornblit B; Munthe-Fog L; Madsen HO; Strøm J; Vindeløv L; Garred P
    Crit Care; 2008; 12(3):R83. PubMed ID: 18577209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia.
    Nagato M; Okamoto K; Abe Y; Higure A; Yamaguchi K
    Crit Care Med; 2009 Jul; 37(7):2181-6. PubMed ID: 19487933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble thrombomodulin attenuates sinusoidal obstruction syndrome in rat through suppression of high mobility group box 1.
    Nakamura K; Hatano E; Miyagawa-Hayashino A; Okuno M; Koyama Y; Narita M; Seo S; Taura K; Uemoto S
    Liver Int; 2014 Nov; 34(10):1473-87. PubMed ID: 24498917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome.
    Gando S; Kameue T; Nanzaki S; Nakanishi Y
    Thromb Haemost; 1996 Feb; 75(2):224-8. PubMed ID: 8815564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.